Direct analysis of mitochondrial toxicity of antiretroviral drugs

AIDS

Volumn 15, Issue 13, 2001, Pages 1687-1694

  Foli, Andrea ^a,b   Benvenuto, Federica ^c   Piccinini, Giampiero ^a,b   Bareggi, Antonella ^a,b   Cossarizza, Andrea ^a   Lisziewicz, Julianna ^a,b   Lori, Franco ^a,b  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^b Section of General Pathology ^*

^c Section of General Pathology   (Italy)

Author keywords

Combination therapy; FACS; Mitochondria; Reverse transcriptase inhibitors; Toxicity

Indexed keywords

ANTIRETROVIRUS AGENT; DIDANOSINE; HYDROXYUREA; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ARTICLE; CONTROLLED STUDY; CYTOFLUOROMETRY; CYTOTOXICITY; DATA ANALYSIS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER FAILURE; LIVER TOXICITY; PANCREAS DISEASE; PANCREATITIS; PRIORITY JOURNAL;

ANTI-HIV AGENTS; BENZIMIDAZOLES; CARBOCYANINES; CELL LINE; DIDANOSINE; DRUG SYNERGISM; FLUORESCENT DYES; HUMANS; HYDROXYUREA; LIVER; MEMBRANE POTENTIALS; MITOCHONDRIA; MITOCHONDRIA, LIVER; PANCREAS; REVERSE TRANSCRIPTASE INHIBITORS; STAINING AND LABELING;

EID: 0035823019     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200109070-00012     Document Type: Article

References (51)

1. Adverse effects of reverse transcriptase inhibitors: Mitochondrial toxicity as common pathway
2. Deoxyribonucleotide analogs as inhibitors and substrates of DNA polymerases
3. Selective action of 3′-azido-3′-deoxythymidine 5′triphosphate on viral reverse transcriptases and human DNA polymerases
4. Mechanism of inhibition of human immunodeficiency virus type 1 reverse transcriptase and human DNA polymerases alpha, beta, and gamma by the 5′-triphosphates of carbovir, 3′-azido-3′-deoxythymidine, 2′,3′-dideoxyguanosine and 3′-deoxythymidine. A novel RNA template for the evaluation of antiretroviral drugs
5. Kinetic analysis of the interaction between the diphosphate of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine, ddCTP, AZTTP, and FIAUTP with the human DNA polymerases
6. The intracellular phosphorylation of (-)-2′-deoxy-3′-thiacytidine (3TC) and the incorporation of 3TC 5′-monophosphate into DNA by HIV-1 reverse transcriptase and human DNA polymerase gamma
7. Selective action of 2′,3′-didehydro-2′,3′-dideoxythymidine triphosphate on human immunodeficiency virus reverse transcriptase and human DNA polymerases
8. Hypothesis: Control of apoptosis by the cellular ATP level
9. Mitochondrial toxicity of antiviral drugs
10. Mitochondrial genetics: A paradigm for aging and degenerative diseases?
11. Hepatomegaly and steatosis in HIV-infected patients receiving nucleoside analog antiretroviral therapy
12. Fulminant hepatic failure associated with 2′,3′-dideoxyinosine (ddl)
13. Didanosine-associated eosinophilia with acute thrombocytopenia
14. Effect of anti-human immunodeficiency virus nucleoside analogs on mitochondrial DNA and its implication for delayed toxicity
15. Potential intracellular target for 2′-3′ dideoxyinosine related pancreatic toxicity
16. Didanosine. An update on its antiviral activity, pharmacokinetic properties and therapeutic efficacy in the management of HIV disease
17. Long-term toxicity/activity profile of 2′,3′-dideoxyinosine in AIDS or AIDS-related complex
18. Hydroxyurea as an inhibitor of human immunodeficiency virus-type 1 replication
19. Low levels of deoxynucleotides in peripheral blood lymphocytes: A strategy to inhibit human immunodeficiency virus type 1 replication
20. Combination of a drug targeting the cell with a drug targeting the virus controls HIV-1 resistance
21. Phase I/II dosing study of once-daily hydroxyurea (HU) alone vs didanosine (ddl) alone vs ddl + HU
22. A placebo-controlled trial of didanosine plus stavudine, with and without hydroxyurea, for HIV infection. The Swiss HIV Cohort Study
23. Hydroxyurea in combination regimens for the treatment of antiretroviral naive, HIV-infected adults
24. Randomized trial of continued IDV/ZDV/3TC vs. switch to IDV/ddl/d4T or IDV/ddl/ d4T plus HU in patients with viral suppression
25. Acute pancreatitis as a common complication of 2′,3′-dideoxyinosine therapy in the acquired immunodeficiency syndrome
26. A dose comparison study of didanosine in patients with very advanced HIV infection who are intolerant to or clinically deteriorate on zidovudine
27. Five-year follow-up of a phase I study of didanosine in patients with advanced human immunodeficiency virus infection
28. A new method for the cytofluorimetric analysis of mitochondrial membrane potential using the J-aggregate forming lipophilic cation 5,5′,6,6′-tetrachloro-1,1′,3,3′- tetraethylbenzimidazolcarbocyanine iodide (JC-1)
29. Protective effect of N-acetylcysteine in tumor necrosis factor-alpha-induced apoptosis in U937 cells: The role of mitochondria
30. Mitochondrial mass and membrane potential in coelomocytes from the earthworm Eisenia foetida: Studies with fluorescent probes in single intact cells
31. Functional heterogeneity of an isolated mitochondrial population revealed by cytofluorometric analysis at the single organelle level
32. Evidence for dissimilar mechanisms of enhancement of inorganic and organic hydroperoxlde cytotoxicity by L-histidine
33. Mitochondria are selective targets for the protective effects of heat shock against oxidative injury
34. Mitochondria alterations and dramatic tendency to undergo apoptosis in peripheral blood lymphocytes during acute HIV syndrome
35. Deregulation of the CD95/CD95L system in lymphocytes from patients with primary acute HIV infection
36. J-aggregate formation of a carbocyanine as a quantitative fluorescent indicator of membrane potential
37. Intracellular heterogeneity in mitochondrial membrane potentials revealed by a J-aggregate-forming lipophilic cation JC-1
38. Conversion of Logarithmic channel numbers into relative linear fluorescence
39. Treatment of HIV disease in the new millennium
40. Comparison of the plasma pharmacokinetics and renal clearance of didanosine during once and twice daily dosing in HIV-1 infected individuals
41. Pharmacokinetics of hydroxyurea in patients infected with human immunodeficiency virus type I
42. The Alpha trial. European/Australian randomized double-blind trial of two doses of didanosine in zidovudine-intolerant patients with symptomatic HIV disease
43. Differential effects of antiretroviral nucleoside analogs on mitochondrial function in HepG2 cells
44. The other human genome: Mitochondrial DNA and disease
45. Mitochondrial medicine
46. Treatment of human immunodeficiency virus infection with hydroxyurea: Virologic and clinical evaluation
47. Hydroxyurea and didanosine as a more potent combination than hydroxyurea and zidovudine
48. Fulminant hepatitis with severe lactate acidosis in HIV-infected patients on didanosine therapy
49. 2′-3′-didanosine-induced mallory bodies in patients with HIV
50. Mitochondrial toxicity-new adverse drug effects
51. Zidovudine and dideoxynucleosides deplete wild-type mitochondrial DNA levels and increase deleted mitochondrial DNA levels in cultured Kearns-Sayre syndrome fibroblasts